title: Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.
abstract: The suppression of oncogenic levels of MYC is sufficient to induce sustained tumor regression associated with proliferative arrest, differentiation, cellular senescence, and/or apoptosis, a phenomenon known as oncogene addiction. However, after prolonged inactivation of MYC in a conditional transgenic mouse model of Eμ-tTA/tetO-MYC T-cell acute lymphoblastic leukemia, some of the tumors recur, recapitulating what is frequently observed in human tumors in response to targeted therapies. Here we report that these recurring lymphomas express either transgenic or endogenous Myc, albeit in many cases at levels below those in the original tumor, suggesting that tumors continue to be addicted to MYC. Many of the recurring lymphomas (76%) harbored mutations in the tetracycline transactivator, resulting in expression of the MYC transgene even in the presence of doxycycline. Some of the remaining recurring tumors expressed high levels of endogenous Myc, which was associated with a genomic rearrangement of the endogenous Myc locus or activation of Notch1. By gene expression profiling, we confirmed that the primary and recurring tumors have highly similar transcriptomes. Importantly, shRNA-mediated suppression of the high levels of MYC in recurring tumors elicited both suppression of proliferation and increased apoptosis, confirming that these tumors remain oncogene addicted. These results suggest that tumors induced by MYC remain addicted to overexpression of this oncogene.
authors.affiliation: Division of Oncology, Department of Medicine and Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
authors.forename: Peter S
authors.initials: PS
authors.lastname: Choi
authors.forename: Jan
authors.initials: J
authors.lastname: van Riggelen
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Gentles
authors.forename: Pavan
authors.initials: P
authors.lastname: Bachireddy
authors.forename: Kavya
authors.initials: K
authors.lastname: Rakhra
authors.forename: Stacey J
authors.initials: SJ
authors.lastname: Adam
authors.forename: Sylvia K
authors.initials: SK
authors.lastname: Plevritis
authors.forename: Dean W
authors.initials: DW
authors.lastname: Felsher
mesh_terms: D000818:Animals; D015870:Gene Expression; D055785:Gene Knockdown Techniques; D016259:Genes, myc; D006801:Humans; D016399:Lymphoma, T-Cell / Q000235:genetics* / Q000628:therapy*; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000235:genetics*; D010641:Phenotype; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000628:therapy*; D034741:RNA, Small Interfering / Q000235:genetics; D013753:Tetracycline Resistance / Q000235:genetics; D015534:Trans-Activators / Q000235:genetics
chemical_list: D034741:RNA, Small Interfering; D015534:Trans-Activators